☆ 4.6 Review

Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis

AUTOIMMUNITY REVIEWS (2022)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Effect of IBD medications on COVID-19 outcomes: results from an international registry

Ryan C. Ungaro et al.

Summary: Combination therapy and thiopurines may be associated with an increased risk of severe COVID-19, while no significant differences were observed when comparing classes of biologicals. These findings warrant confirmation in large population-based cohorts.

GUT (2021)

Add to Collection

Editorial Material Rheumatology

Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis

Andrea Rubbert-Roth et al.

LANCET RHEUMATOLOGY (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease

Michael D. Kappelman et al.

GASTROENTEROLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis

Anupam Kumar Singh et al.

Summary: The risk of SARS-CoV-2 infection in patients with inflammatory bowel disease is comparable to the general population, with worse outcomes in ulcerative colitis, patients on steroids or 5-aminosalicylates, but better outcomes with biological agents.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)

Add to Collection

Letter Dermatology

COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers

G. Damiani et al.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2021)

Add to Collection

Article Immunology

Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies-A Danish population-based cohort study

Mohamed Attauabi et al.

Summary: The study found a lower occurrence but a more severe disease course of COVID-19 among patients with IMIDs, associated with the use of systemic steroids and suspension of other immunosuppressants. Therefore, it emphasizes the importance of weighing risks before suspending immunosuppressants during COVID-19.

JOURNAL OF AUTOIMMUNITY (2021)

Add to Collection

Letter Rheumatology

Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases

Brian J. Boyarsky et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Rheumatology

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

Michael Markus Bonelli et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

David Simon et al.

Summary: Immune response against SARS-CoV-2 is delayed and reduced in patients with immune-mediated inflammatory diseases, regardless of treatment.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Rheumatology

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases

Robert Spiera et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Ulf M. Geisen et al.

Summary: In this study, the efficacy and safety of anti-SARS-CoV-2 mRNA vaccines in immunosuppressed patients were compared with healthy controls. The results showed that all study participants developed antibodies, with lower IgG titres in patients compared to controls. Side effects were minimal and no disease flares were observed, demonstrating the efficiency and safety of mRNA vaccines in this cohort despite its small size.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Dermatology

Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease

A. Al-Janabi et al.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Letter Dermatology

COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast

A. Pacifico et al.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

Serre-Yu Wong et al.

GASTROENTEROLOGY (2021)

Add to Collection

Article Immunology

Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination

Abdulla Watad et al.

Summary: Although temporally-associated with SARS-CoV-2 vaccination, new-onset or flare of immune-mediated diseases (IMDs) appear rare. Most cases are of moderate severity and responsive to therapy, although some severe flares occurred.

VACCINES (2021)

Add to Collection

Letter Rheumatology

SARS-COV-2 vaccination after stem cell transplantation for scleroderma

Doron Rimar et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Rheumatology

Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'

Giuseppe A. Ramirez et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Rheumatology

Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'

Timm H. Westhoff et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Rheumatology

Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'

Jesse Veenstra et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2

Yolanda Braun-Moscovici et al.

Summary: The vast majority of patients with inflammatory rheumatic diseases developed a significant humoral response following the administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2 virus. Only minor side effects were reported and no apparent impact on IRD activity was noted.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Rheumatology

Correspondence on 'Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'

Chiara Salviani et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity

Daniel Mrak et al.

Summary: The study found that RTX-treated patients can develop SARS-CoV-2-specific antibodies after vaccination, but only if peripheral B cells at least partially repopulate. Additionally, more than half of the vaccinated patients developed SARS-CoV-2-specific T cells, which may provide protective effects regardless of humoral immune responses.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Rheumatology

High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases

Jake A. Ruddy et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Rheumatology

Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis

Serena Bugatti et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Rheumatology

Correspondence on Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'

Larissa Valor-Mendez et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

Rebecca H. Haberman et al.

Summary: The study found that patients with immune-mediated inflammatory diseases (IMIDs) on methotrexate treatment showed impaired humoral and cellular immune response to COVID-19 mRNA vaccines, while healthy subjects and IMID patients on biologic treatments demonstrated strong antibody responses. These results suggest that different strategies may need to be explored to enhance immunization efficacy for IMID patients on methotrexate treatment.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Review Gastroenterology & Hepatology

Vaccinations in patients with inflammatory bowel disease

Fabio Salvatore Macaluso et al.

Summary: Vaccination is crucial in managing patients with inflammatory bowel disease (IBD), yet vaccination rates are low due to lack of awareness among healthcare providers and patients. Current evidence-based recommendations for vaccines and prevention of infectious diseases in IBD patients should be widely promoted and implemented.

DIGESTIVE AND LIVER DISEASE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications

Nabeel Khan et al.

Summary: The study found that full vaccination against SARS-CoV-2 has an effectiveness of approximately 80.4% in patients with inflammatory bowel disease who may be taking immunosuppressive medications.

GASTROENTEROLOGY (2021)

Add to Collection

Article Rheumatology

Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly

Emire Seyahi et al.

Summary: Patients with immune-mediated diseases had lower antibody response to the inactivated COVID-19 vaccine compared to healthy controls, especially those using immunosuppressive or immune-modulating drugs. Older age was also associated with lower antibody titers in both patient and control populations. Further studies are needed to determine if booster doses are necessary for these individuals.

RHEUMATOLOGY INTERNATIONAL (2021)

Add to Collection

Review Immunology

Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms

Federica Raucci et al.

AUTOIMMUNITY REVIEWS (2020)

Add to Collection

Review Immunology

Covid-19 and autoimmunity

Michael Ehrenfeld et al.

AUTOIMMUNITY REVIEWS (2020)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Maheshi N. Ramasamy et al.

LANCET (2020)

Add to Collection

Article Psychiatry

How to perform a meta-analysis with R: a practical tutorial

Sara Balduzzi et al.

EVIDENCE-BASED MENTAL HEALTH (2019)

Add to Collection

Review Rheumatology

Vaccinations in patients with immune-mediated inflammatory diseases

Jean-Francois Rahier et al.

RHEUMATOLOGY (2010)

Add to Collection

Article Medicine, General & Internal

Meta-analysis of observational studies in epidemiology - A proposal for reporting

DF Stroup et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.